Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
Name | Price | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Olaratumab Biosimilar - Anti-PDGF-R alpha mAb - Research Grade | Login | Olaratumab Biosimilar - Anti-PDGF-R alpha mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Sarilumab Biosimilar - Anti-IL-6R mAb - Research Grade | Login | Sarilumab Biosimilar - Anti-IL-6R mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Sarilumab Biosimilar - Anti-IL-6R mAb - Research Grade | Login | Sarilumab Biosimilar - Anti-IL-6R mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Tocilizumab Biosimilar - Anti-IL-6R mAb - Research Grade | Login | Tocilizumab Biosimilar - Anti-IL-6R mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Tocilizumab Biosimilar - Anti-IL-6R mAb - Research Grade | Login | Tocilizumab Biosimilar - Anti-IL-6R mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade | Login | Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade | Login | Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade | Login | Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade | Login | Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Abagovomab Biosimilar - Anti-idiotope of anti-Mus musculus monoclonal antibody OC126 mAb - Research Grade | Login | Abagovomab Biosimilar - Anti-idiotope of anti-Mus musculus monoclonal antibody OC126 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Abagovomab Biosimilar - Anti-idiotope of anti-Mus musculus monoclonal antibody OC126 mAb - Research Grade | Login | Abagovomab Biosimilar - Anti-idiotope of anti-Mus musculus monoclonal antibody OC126 mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Edrecolomab Biosimilar - Anti-EPCAM mAb - Research Grade | Login | Edrecolomab Biosimilar - Anti-EPCAM mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Edrecolomab Biosimilar - Anti-EPCAM mAb - Research Grade | Login | Edrecolomab Biosimilar - Anti-EPCAM mAb - Research Grade | ||||||||||||||||
|
||||||||||||||||||
Claudin-18 (CLDN18) | Login | Claudin-18 (CLDN18) | ||||||||||||||||
|
||||||||||||||||||
FLT3LG protein(FLT3LG) | Login | FLT3LG protein(FLT3LG) | ||||||||||||||||
|
||||||||||||||||||
ProGRP | Login | ProGRP | ||||||||||||||||
|
||||||||||||||||||
Receptor-type tyrosine-protein phosphatase C (PTPRC) CD45 | Login | Receptor-type tyrosine-protein phosphatase C (PTPRC) CD45 | ||||||||||||||||
|
||||||||||||||||||
Mucin-1(Met1-Pro146) | Login | Mucin-1(Met1-Pro146) | ||||||||||||||||
|
||||||||||||||||||
Mucin-1(Ala927-Gly1158) | Login | Mucin-1(Ala927-Gly1158) | ||||||||||||||||
|
||||||||||||||||||
Mucin-1(Ser24-Pro146) | Login | Mucin-1(Ser24-Pro146) | ||||||||||||||||
|
||||||||||||||||||
Mucin-1(Thr931-Gly1158) | Login | Mucin-1(Thr931-Gly1158) | ||||||||||||||||
|
||||||||||||||||||
Trans-acting T-cell-specific transcription factor GATA-3(GATA3) | Login | Trans-acting T-cell-specific transcription factor GATA-3(GATA3) | ||||||||||||||||
|
||||||||||||||||||
Cytotoxic T-lymphocyte protein 4(CTLA4)(Ala37-Asp161) | Login | Cytotoxic T-lymphocyte protein 4(CTLA4)(Ala37-Asp161) | ||||||||||||||||
|
||||||||||||||||||
Adiponectin(ADIPOQ) | Login | Adiponectin(ADIPOQ) | ||||||||||||||||
|
||||||||||||||||||
Arginase-1(ARG1) | Login | Arginase-1(ARG1) | ||||||||||||||||
|